Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
about
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsInflammation, Immune Activation, and Antiretroviral Therapy in HIVAbacavir has no prothrombotic effect on platelets in vitro.The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitroChanges from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
P2860
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@ast
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@en
type
label
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@ast
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@en
prefLabel
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@ast
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@en
P2093
P2860
P356
P1476
Evaluation of cardiovascular b ...... ts (SUPPORT): 96-week results.
@en
P2093
Belinda Ha
Britt Stancil
Catherine Butkus Small
Edwin DeJesus
Franco Felizarta
Gregory Huhn
Howard Edelstein
Keith Pappa
Louis Sloan
P2860
P2888
P356
10.1186/1471-2334-13-269
P577
2013-06-07T00:00:00Z
P5875
P6179
1051376852